XLO — Xilio Therapeutics Share News
0.000.00%
Last trade - 00:00- $49.81m
- -$86.23m
- $43.77m
Xilio Therapeutics surges on license deal with Gilead, job cuts
Brief: Gilead And Xilio Announce Exclusive License Agreement For Tumor-Activated Il-12 Program
Brief: Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Brief: Xilio Therapeutics Says Co Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Xilio Therapeutics Announces Initiation Of Enrollment For Phase 1 Combination Trial Of XTX101
Brief: Xilio Therapeutics Q3 Net Income USD -16.748 Million
Brief: Xilio Promotes Katarina Luptakova To Chief Medical Officer And Scott Coleman To Chief Development Officer
Brief: Xilio Therapeutics, Inc. Q2 basic EPS USD -0.7
Brief: Xilio Therapeutics Announces Pipeline And Business Updates And Q2 Financial Results
Brief: Xilio Therapeutics Announces Preliminary Clinical Data From Phase 1 Trial Of Xtx101, A Tumor-Activated, FC-Enhanced Anti-Ctla-4, In Patients With Advanced Solid Tumors
Brief: Xilio Therapeutics Announces First Quarter 2023 Financial Results
Xilio Therapeutics rises after Merck reports 5.4% stake
Brief: Merck & Co., Inc. Says Has 5.4% Passive Stake In Xilio Therapeutics, Inc. As Of March 30, 2023 - SEC Filing
Brief: Xilio Therapeutics Announces Pipeline And Business Updates For Q4 And Full Year 2022 Financial Results
Brief: Xilio Therapeutics Inc Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Brief: Xilio Therapeutics Announces Third Quarter Results
Brief: Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data For XTX101
Brief: Xilio Therapeutics Inc - On July 25, Salvatore Giovine Notified Of His Decision To Resign As Chief Financial Officer
Brief: Xilio Therapeutics Announces Promotion Of Martin Huber To President